Two regulators that rarely move in step published a shared framework on the same day. That tells you where drug development regulation is heading.
Short answer: On 14 January 2026 the FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development, covering the full medicines lifecycle with a human-centric, risk-based approach. They are not formal guidance, but they signal what both regulators will expect.
Key takeaways
- On 14 January 2026 the US Food and Drug Administration and the European Medicines Agency jointly released the Guiding Principles of Good AI Practice in Drug Development, a set of ten.
- 130 live listings in this category publish a rate, at a median top-of-range of $65 an hour and a ceiling of $230.
- The work is remote contract work, asynchronous, with no set hours and no guaranteed volume.
- Applications screen on a short skills assessment rather than a resume or interview.
What was reported
The finding
On 14 January 2026 the US Food and Drug Administration and the European Medicines Agency jointly released the Guiding Principles of Good AI Practice in Drug Development, a set of ten high-level principles intended to steer safe and responsible AI use across the product lifecycle. The principles span early research and clinical trials through manufacturing and post-market safety surveillance, and emphasise a human-centric, risk-based approach to AI adoption. The document is not formal industry guidance, but the agencies frame it as a foundation for future guidance, standards and harmonised regulatory expectations from international regulators and standards bodies.
The ten principles cover the full lifecycle, from early research and clinical trials through manufacturing and post-market safety surveillance, and the framing is explicitly human-centric and risk-based. They are not binding guidance yet. The agencies describe them as a foundation for future guidance, standards and harmonised expectations, which is regulator language for this is what we will be asking about.
What the listings pay
The human-centric framing is the operative part for anyone weighing this work. A risk-based regime does not ask whether you used AI. It asks who checked it, against what, and whether that person was competent to do so.
| # | Role | Advertised rate | Platform |
|---|---|---|---|
| 1 | Disease-Area Clinician, Trial Endpoints & Prescribing | $150 to $230 an hour | Mercor |
| 2 | Pharma Commercial Forecasting Expert, Launch Curves | $130 to $210 an hour | Mercor |
| 3 | Therapeutic Area & Clinical Survey Expert | $200 to $200 an hour | Mercor |
| 4 | Clinician (Oncology / Hematology) | $160 to $200 an hour | micro1 |
| 5 | Biotech Investment Analyst, Drug Asset & Company Assessment | $120 to $200 an hour | Mercor |
| 6 | Multilingual Primary Care Physician (MD): Clinical Documentation & AI Evaluation | $170 to $190 an hour | Mercor |
| 7 | Medical Safety Expert | $140 to $190 an hour | Mercor |
| 8 | Clinical Law Professor / Clinic Director | $180 to $180 an hour | Mercor |
| 9 | Multilingual Inpatient Hospitalist (MD): Clinical Documentation & AI Evaluation | $170 to $170 an hour | Mercor |
| 10 | Clinical Regulatory Expert | $130 to $170 an hour | Mercor |
Source: 130 live listings on this board that publish a rate, read directly from each posting on 2026-09-06. Listings without a published rate are excluded rather than estimated.
How this compares across the board
A rate only means something next to the alternatives. This is every category we track with at least five listings publishing a rate, ranked by median top-of-range, so you can see where this work sits rather than taking a single number on trust.
| Category | Listings | Median low | Median top | Highest |
|---|---|---|---|---|
| Legal | 95 | $100 | $140 | $400 |
| Medical | 68 | $77 | $120 | $400 |
| Consulting | 45 | $80 | $120 | $280 |
| Finance | 94 | $80 | $110 | $280 |
| Engineering | 114 | $70 | $100 | $300 |
| Research/PhD | 132 | $70 | $90 | $280 |
| Writing | 36 | $40 | $80 | $280 |
| Bilingual | 78 | $44 | $52 | $120 |
| Annotation | 25 | $12 | $24 | $120 |
Same source and date as above. Categories are matched on listing title, so a role can appear in more than one.
What it means for you
That creates durable demand for people who can evidence a review rather than perform one. Across 130 live clinical, pharmaceutical and regulatory listings on our board that publish a rate, the median top-of-range is $65 an hour, reaching $230.
Why a human-centric framing changes the work
Risk-based regulation places the burden on the sponsor to show that its controls were proportionate to the risk. When AI is in the pipeline, that means documenting what the model produced, what a qualified person checked, and why the check was adequate.
This is why the demand is for people with regulatory literacy rather than AI expertise. The scarce skill is knowing what an inspector will ask and being able to answer it in writing.
The FDA's own position is instructive. It deployed Elsa agency-wide while its reviewers reported inaccuracies and incomplete data, which is precisely the situation these principles are written for: use the tool, and keep a competent human accountable for the output.
What this means across the medicines lifecycle
Early research and target identification is where generative tools are furthest along, as the Insilico rentosertib programme showed by reaching Phase III on an AI-designed molecule.
Clinical trials are where eligibility logic and safety narratives carry the highest cost of silent error, which is why chart-screening and trial-matching systems are getting the most scrutiny.
Manufacturing and post-market surveillance are the least discussed and arguably the most consequential, since adverse event signal detection failing quietly is the failure mode nobody sees until it is large.
Who should apply
Two checks before you spend time on an application. Confirm the role accepts applicants from your country with the eligibility checker, since a meaningful share of listings carry location requirements. Then run the advertised rate through the take-home calculator, because this is contract work and the headline figure is before self-employment tax.
Applications complete on the hiring platform and usually take a few minutes, with a short skills assessment in place of an interview. Fill in every credential, language and professional background field on your profile. Those are what route you to the better paid listings, and most applicants leave them blank.
Frequently asked questions
What did the FDA and EMA publish?
Ten Guiding Principles of Good AI Practice in Drug Development, released jointly on 14 January 2026, covering the full medicines lifecycle.
Are the principles legally binding?
No. They are high-level principles rather than formal industry guidance, but the agencies frame them as a foundation for future guidance and harmonised regulatory expectations.
What do they emphasise?
A human-centric, risk-based approach to AI adoption across early research, clinical trials, manufacturing and post-market safety surveillance.
Why does that create work?
Risk-based regulation asks who checked the AI output, against what, and whether they were competent. That requires people who can evidence a review, not just perform one.
What does regulatory AI work pay?
Across 130 live clinical, pharmaceutical and regulatory listings publishing a rate, the median top-of-range is $65 an hour, reaching $230.
What background do these listings want?
Regulatory affairs, clinical development, pharmacovigilance or quality experience. Knowing what an inspector asks is the specific value.
Is the FDA using AI itself?
Yes. It deployed its Elsa tool agency-wide, while its own reviewers have reported responses containing inaccuracies or incomplete data.
Sources
See every live role
The full board updates several times a week, with the advertised rate on each listing and closed roles removed.